The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First results for Australasian Gastrointestinal Trials Group (AGITG) control net study: Phase II study of 177Lu-octreotate peptide receptor radionuclide therapy (LuTate PRRT) +/- capecitabine, temozolomide (CAPTEM) for midgut neuroendocrine tumors (mNETs).
 
Nick Pavlakis
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Ipsen; Ipsen; Ipsen; Ipsen; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche; Takeda; Takeda; Takeda; Takeda
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Roche; Roche; Roche; Roche
 
David Turner Ransom
Research Funding - Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst)
Travel, Accommodations, Expenses - Ipsen; Ipsen; Ipsen; Ipsen; Novartis; Novartis; Novartis; Novartis
 
David Wyld
Honoraria - Ipsen; Ipsen; Ipsen; Ipsen
Consulting or Advisory Role - Ipsen; Ipsen; Ipsen; Ipsen
Speakers' Bureau - Ipsen; Ipsen; Ipsen; Ipsen
Research Funding - Ipsen; Ipsen; Ipsen; Ipsen
Travel, Accommodations, Expenses - Ipsen; Ipsen; Ipsen; Ipsen; Novartis; Novartis; Novartis; Novartis
 
Katrin Marie Sjoquist
Honoraria - Merck; Merck; Merck; Merck
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst)
 
Rebecca Asher
No Relationships to Disclose
 
Val Gebski
No Relationships to Disclose
 
Kate Wilson
No Relationships to Disclose
 
Andrew Ddembe Kiberu
No Relationships to Disclose
 
Matthew E. Burge
Stock and Other Ownership Interests - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; coclear; coclear; coclear; coclear; CSL Limited; CSL Limited; CSL Limited; CSL Limited; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; pfizer; pfizer; pfizer; pfizer
Honoraria - Amgen; Amgen; Amgen; Amgen; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; ipsen; ipsen; ipsen; ipsen; Roche; Roche; Roche; Roche
Patents, Royalties, Other Intellectual Property - funding for an investigator initiated prospective trial (Inst); funding for an investigator initiated prospective trial (Inst); funding for an investigator initiated prospective trial (Inst); funding for an investigator initiated prospective trial (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Roche; Roche; Roche; Roche; Roche; Roche; Roche; Roche
 
William Macdonald
No Relationships to Disclose
 
Paul Roach
No Relationships to Disclose
 
David A Pattison
No Relationships to Disclose
 
Patrick Butler
No Relationships to Disclose
 
Timothy Jay Price
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen
 
Michael Michael
Consulting or Advisory Role - Ipsen; Ipsen; Ipsen; Ipsen; Merck; Merck; Merck; Merck
 
Benjamin James Lawrence
Employment - Canopy Cancer Care; Canopy Cancer Care; Canopy Cancer Care; Canopy Cancer Care
Leadership - Canopy Cancer Care; Canopy Cancer Care; Canopy Cancer Care; Canopy Cancer Care
Stock and Other Ownership Interests - Canopy Cancer Care; Canopy Cancer Care; Canopy Cancer Care; Canopy Cancer Care
 
Dale L. Bailey
No Relationships to Disclose
 
John Charles Leyden
No Relationships to Disclose
 
John Raymond Zalcberg
Stock and Other Ownership Interests - Aimmune; Aimmune; Aimmune; Aimmune; Alnylam; Alnylam; Alnylam; Alnylam; Biomarin; Biomarin; Biomarin; Biomarin; Bluebird Bio; Bluebird Bio; Bluebird Bio; Bluebird Bio; Cochlear; Cochlear; Cochlear; Cochlear; CSL Limited; CSL Limited; CSL Limited; CSL Limited; Dova Pharmaceuticals; Dova Pharmaceuticals; Dova Pharmaceuticals; Dova Pharmaceuticals; GW Pharmaceuticals; GW Pharmaceuticals; GW Pharmaceuticals; GW Pharmaceuticals; Juno Therapeutics; Juno Therapeutics; Juno Therapeutics; Juno Therapeutics; Kiadis Pharma; Kiadis Pharma; Kiadis Pharma; Kiadis Pharma; Kite, a Gilead company; Kite, a Gilead company; Kite, a Gilead company; Kite, a Gilead company; Sage Therapeutics; Sage Therapeutics; Sage Therapeutics; Sage Therapeutics; TherapeuticsMD; TherapeuticsMD; TherapeuticsMD; TherapeuticsMD; Vertex; Vertex; Vertex; Vertex
Honoraria - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Halozyme; Halozyme; Halozyme; Halozyme; Merck Serono; Merck Serono; Merck Serono; Merck Serono; pfizer; pfizer; pfizer; pfizer; Specialised Therapeutics; Specialised Therapeutics; Specialised Therapeutics; Specialised Therapeutics; Targovax; Targovax; Targovax; Targovax
Consulting or Advisory Role - Halozyme; Halozyme; Halozyme; Halozyme; Lipotek; Lipotek; Lipotek; Lipotek; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Pfizer; Pfizer; Pfizer; Pfizer; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical; Targovax; Targovax; Targovax; Targovax
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Baxalta/Shire (Inst); Baxalta/Shire (Inst); Baxalta/Shire (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Specialised Therapeutics (Inst); Specialised Therapeutics (Inst); Specialised Therapeutics (Inst); Specialised Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Deciphera; Deciphera; Deciphera; Deciphera; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme
 
J. Harvey Turner
No Relationships to Disclose